The Critical Role of Data Quality and Data Culture in Successful AI Solutions for Pharma

In the pharmaceutical and life sciences sectors, the integration of artificial intelligence (AI) is rapidly transforming research, development, manufacturing, and patient care. However, the success of AI initiatives is fundamentally dependent on two interlinked pillars: data quality and data culture. High-quality, trustworthy data is the lifeblood of effective AI, while a robust data culture ensures that data-driven decision-making is embedded throughout the organization. This report provides a comprehensive analysis of these concepts, their assessment, their criticality in regulated environments, common challenges, remediation strategies, governance models, supporting technologies, regulatory nuances, leadership imperatives, and a practical roadmap for building readiness. Drawing on authoritative sources, including the FDA, EMA, WHO, ISO, industry case studies, and leading frameworks, this report offers actionable insights for leaders seeking to maximize the value and compliance of AI in pharma and life sciences.

1.1 Data Quality: Meaning and Examples

Data quality refers to the degree to which information is accurate, complete, consistent, reliable, and fit for its intended purpose. In regulated industries like pharmaceuticals, this is not simply a technical aspiration; it is a legal and ethical imperative. FDA CGMP data-integrity guidance explains that CGMP data should be attributable, legible, contemporaneously recorded, original or a true copy, and accurate. Organizations may also use ALCOA+ terminology as an internal data-integrity framework, but applicable legal and regulatory requirements remain context- and jurisdiction-specific. FDA’s data-integrity guidance describes its nonbinding recommendations for drug CGMP records.

Think of a clinical trial: high data quality means that required data are complete, or that missingness is documented, justified, and handled appropriately; data accurately reflect the patient’s condition; formats and units are used consistently; and each entry is traceable to the responsible individual and the time it was created. Without this foundation, trial results risk being invalidated, regulatory approval delayed, or worse, patient safety compromised.

Key Attributes of Data Quality in Pharmaceutical and Life Sciences

• Accuracy Accuracy is the cornerstone of trust. Lab results must reflect true measurements, free from transcription errors or instrument drift. A single inaccurate data point in a clinical study can cascade into flawed conclusions, undermining both scientific integrity and regulatory confidence.

• Completeness Completeness means nothing is left out, even failed tests, anomalies, or outliers must be retained. In pharma, the absence of data can be as damaging as incorrect data. Regulators expect a full picture, not a curated one, because gaps can conceal risks or invalidate findings.

• Consistency Consistency ensures that data speaks the same language across systems and studies. Units, formats, and nomenclature must be standardized. Imagine comparing blood pressure readings where one dataset uses mmHg and another uses kPa, without consistency, analysis becomes error‑prone and AI models misinterpret signals.

• Reliability Reliability is about confidence in the process. Data must be generated and maintained under validated, controlled conditions. In manufacturing, this means instruments are calibrated, processes are documented, and systems are audited. Reliable data is the bedrock of reproducibility, which regulators and scientists alike demand.

• Traceability Traceability ties every data point back to its origin: who created it, when, and how. This attribute is especially critical in regulated environments, where audit trails must demonstrate accountability. Traceability transforms data from isolated numbers into a narrative of responsibility and compliance.

Consider manufacturing: batch records must be accurate and complete to ensure product quality and patient safety. A missing temperature reading or an incorrect timestamp can trigger batch rejection, recalls, or regulatory action. In this context, data quality is not abstract, it directly determines whether medicines reach patients safely and on time.

Data culture is the collective mindset, behaviors, and values that shape how an organization treats data as a strategic asset. It is not just about policies or technology, it is about people. A strong data culture emerges when leadership demonstrates commitment, teams embrace data‑driven decision‑making, and employees at every level feel empowered to engage with data responsibly. In this environment, data is not seen as a burden or a compliance checkbox, but as a foundation for trustworthy decisions.

At a leading pharmaceutical company, data culture is evident when lab technicians understand the importance of accurate data entry, managers proactively surface issues rather than hiding them, and executives rely on data insights to guide strategic choices instead of leaning solely on intuition or hierarchy. This shared accountability transforms data from a static resource into a dynamic force for discovery, compliance, and competitive advantage.

Key Elements of a Healthy Data Culture

• Leadership Commitment - Culture begins at the top. Executives must champion data initiatives, allocate resources, and model data‑driven behaviors. When leaders consistently ask for evidence, reference dashboards, and reward data‑based decisions, they signal that data is central to the organization’s success.

• Empowerment - A healthy data culture ensures that employees at all levels have access to the data they need and the skills to use it effectively. Empowerment means training staff in data literacy, providing intuitive tools, and removing barriers that keep data siloed. When a scientist can easily query trial data or a quality manager can visualize manufacturing trends, data becomes democratized.

• Collaboration - Data challenges rarely belong to one department. Business, IT, and quality teams must work together to solve problems and align standards. Collaboration ensures that data governance is not an isolated IT function but a shared responsibility across the enterprise.

• Transparency - In strong data cultures, issues are surfaced and addressed openly. Rather than hiding errors or fearing blame, employees are encouraged to report anomalies and gaps. Transparency builds trust, both internally and with regulators, and ensures that problems are corrected before they escalate.

• Continuous Improvement - Data culture is not static. Organizations must regularly review practices, update standards, and refine processes. Continuous improvement signals that data quality and integrity are evolving goals, not one‑time achievements.

Consider a company that rewards employees for identifying and correcting data integrity issues rather than penalizing them. This approach can foster a culture where data quality is everyone’s responsibility. FDA states that management should create a quality culture in which employees understand data integrity as a core organizational value and are encouraged to identify and promptly report issues. FDA’s data-integrity guidance

2.1 Data Quality Metrics

Pharmaceutical and life sciences organizations cannot rely on intuition when it comes to data quality, they must measure it systematically. Metrics provide the evidence needed to demonstrate compliance, identify weaknesses, and enable effective AI solutions. Without quantifiable measures, data quality remains an abstract concept; with them, it becomes a tangible driver of operational excellence and regulatory trust.

Several key metrics are commonly used across pharma and life sciences manufacturing and quality systems:

• Batch Record Accuracy Rate This measures the percentage of batch records that are correct on the first review. A high accuracy rate signals that processes are well‑controlled and documentation practices are robust. When accuracy slips, it often points to systemic issues such as training gaps or poorly designed workflows.

• Data Entry Completeness Completeness reflects the proportion of required fields that are filled in each record. Missing data can be as damaging as incorrect data, especially in regulated environments where every detail matters. Completeness ensures that regulators and AI systems alike have the full picture.

• Review Cycle Time This metric tracks the time taken to review and approve data for batch release. Long cycle times can delay production and market delivery, while shorter, well‑controlled cycles indicate efficiency and confidence in data integrity.

• Data Consistency Across Systems Consistency measures the degree to which data matches across manufacturing, laboratory, and enterprise systems. In an era of digital transformation, where AI models often pull from multiple sources, consistency is critical. A mismatch between systems can lead to flawed analytics or regulatory findings.

• Error Rate Error rate captures the frequency of data errors detected during audits or reviews. A low error rate demonstrates strong controls and reliable processes, while a high rate signals risk exposure and the need for remediation.

Table 1: Example Data Quality Metrics in Pharma Manufacturing

These metrics provide a quantitative basis for continuous improvement. Organizations should establish baselines, targets, and investigation criteria that are appropriate to each process, system, and product-risk profile. In this way, metrics become more than numbers: they help organizations identify weaknesses, demonstrate control, optimize operations, and prepare data for AI use.

2.2 Data Quality Maturity Models

Maturity models provide organizations with a structured way to benchmark their data quality capabilities and identify areas for improvement. Rather than treating data quality as a binary, good or bad, maturity models recognize that organizations evolve over time, moving through stages of sophistication as they build stronger practices, technologies, and cultures.

The Enterprise Data Strategy Maturity Model is one widely used framework. It assesses four key categories: Data, Technology, Process, and People. Together, these dimensions capture not only the technical aspects of data management but also the human and organizational behaviors that determine whether data quality can truly support advanced initiatives like AI.

Stages of Data Quality Maturity

1. Ad hoc At this stage, data quality is managed reactively. Issues are addressed only when they become urgent, and there are no formal processes or governance structures in place. Organizations often rely on individual heroics, a quality manager catching errors or an IT analyst patching systems, rather than systemic controls.

2. Defined Basic policies and procedures begin to emerge. Data quality standards are documented, and teams start to recognize the importance of consistent practices. However, enforcement may be uneven, and measurement is limited. Defined maturity is often the turning point where leadership begins to see data as a strategic asset rather than a compliance burden.

3. Managed At the managed stage, data quality is measured and monitored systematically. Metrics such as accuracy, completeness, and consistency are tracked, and governance processes are embedded into daily operations. Technology solutions like data catalogs, validation tools, and audit trails support these efforts. Managed maturity signals that the organization has moved beyond firefighting into proactive stewardship.

4. Optimized In the optimized stage, data quality is continuously improved and aligned with business goals. Feedback loops ensure that lessons learned are incorporated into processes, and advanced technologies such as AI‑driven anomaly detection or automated lineage tracking are deployed. Optimized organizations treat data quality as a living system, evolving alongside their strategic priorities.

Illustrative Example

A pharmaceutical organization can use a data maturity assessment to evaluate data integration and governance practices. If the assessment identifies gaps in cataloging and traceability, a unified data catalog and lineage capability can help make data assets more discoverable and their transformations easier to investigate. Any claimed improvement in trust, adoption, submission readiness, or operational performance should be measured against a documented baseline.

3.1 Data Culture Assessment Tools

Assessing data culture is not a one‑dimensional exercise. Because culture lives in both attitudes and behaviors, organizations must combine quantitative measures with qualitative insights to capture the full picture. Specialized data culture consultants can help organizations navigate this assessment process effectively. Numbers can reveal patterns, but conversations and observations uncover the “why” behind those patterns. Together, these approaches help leaders understand whether data is truly valued as a strategic asset or treated as an afterthought.

• Surveys Surveys provide a broad snapshot of employee attitudes, behaviors, and perceptions regarding data. They can reveal whether staff feel confident in their data literacy, whether they trust the systems they use, and whether they believe leadership prioritizes data integrity. A well‑designed survey can highlight gaps between leadership’s intentions and employees’ lived experiences.

• Interviews and Focus Groups While surveys capture breadth, interviews and focus groups provide depth. These conversations uncover the nuances of data practices, the challenges employees face, and the cultural barriers that may prevent data from being used effectively. For example, a focus group might reveal that scientists hesitate to report data issues because they fear blame, signaling a need for cultural change.

• Behavioral Indicators Actions often speak louder than words. Tracking behavioral indicators, such as how often employees report data issues, whether cross‑functional teams collaborate on data challenges, and how frequently data is used in decision‑making, provides tangible evidence of culture in practice. These indicators show whether data quality is embedded in daily routines or treated as an occasional concern.

• Benchmarking Benchmarking allows organizations to compare their data culture against industry peers. This external perspective helps leaders understand whether their practices are ahead of the curve, average, or lagging. Benchmarking also provides inspiration, showing what “good” looks like and offering models to emulate.

Example in Practice

The Parenteral Drug Association (PDA) provides quality-culture resources for pharmaceutical organizations. Organizations can combine employee feedback with behavioral indicators to identify strengths and weaknesses and build a roadmap for cultural improvement. PDA Quality Culture resources

3.2 Key Indicators of a Healthy Data Culture

A healthy data culture is not defined by a single policy or initiative, it is revealed in the everyday behaviors and choices of an organization. When culture is strong, data becomes a trusted companion in decision‑making, and employees feel empowered to treat it as a shared responsibility rather than a burden. Several indicators consistently signal that an organization has achieved this level of maturity.

• Leadership Engagement Culture begins with leaders who actively participate in data initiatives and communicate their importance. When executives reference dashboards in meetings, ask probing questions about data integrity, and allocate resources to strengthen data practices, they set the tone for the entire organization. Leadership engagement transforms data from a technical issue into a strategic priority.

• Employee Empowerment Empowerment means that staff are not only trained in data literacy but also encouraged to use data in their daily work. A scientist who can confidently query trial results or a quality manager who can visualize manufacturing trends demonstrates that data is accessible and usable. Empowerment ensures that data is democratized, not siloed.

• Open Reporting In a healthy culture, data integrity issues are reported and addressed without fear of reprisal. Employees feel safe to surface anomalies, knowing they will be met with problem‑solving rather than punishment. This openness builds resilience: issues are corrected quickly, and trust in the system grows stronger.

• Collaboration Data culture thrives when teams share insights across functions. Business, IT, and quality groups work together to solve challenges, ensuring that data governance is not an isolated responsibility but a collective effort. Collaboration breaks down silos and creates a unified approach to data stewardship.

• Recognition Successes in data‑driven projects are celebrated and shared. Recognition reinforces the value of data and motivates employees to continue investing in its quality. Whether it’s a team that reduced error rates through better validation or a department that accelerated decision‑making with analytics, recognition turns data achievements into cultural milestones.

Example in Practice

Quality culture can have an operational impact, but outcomes should be measured against an organization’s own baseline and should not be treated as universal benchmarks. When leadership engages, employees are empowered, reporting is open, collaboration is routine, and recognition is consistent, organizations can strengthen data-integrity practices and support responsible AI adoption.

4.1 The AI Imperative: Data as the Differentiator

Artificial intelligence has become a powerful force in pharmaceutical and life sciences innovation, but the models themselves are increasingly commoditized. Algorithms can be licensed, replicated, or adapted with relative ease. What cannot be commoditized is the data that fuels them. Proprietary, high‑quality data is the true differentiator for pharmaceutical and life sciences companies, shaping whether AI delivers transformative insights or misleading noise.

When AI models are trained on poor‑quality, incomplete, or biased data, results can be unreliable and difficult to validate. In this context, data quality is a technical, scientific, and governance prerequisite.

Consider drug discovery. AI models designed to identify novel therapeutic targets or predict clinical outcomes require harmonized and fit-for-purpose datasets. If datasets are inconsistent—for example, if labs report results in different units or patient records contain transcription errors—the model may generate misleading results or overlook relevant signals.

The lesson is clear: in the era of commoditized AI, data is the differentiator. Companies that invest in rigorous data quality practices and cultivate a strong data culture will not only accelerate discovery but also build trust with regulators, partners, and patients. Those that neglect data integrity risk turning AI into a liability rather than an asset.

4.2 Regulatory and Business Risks

The risks of poor data quality extend far beyond technical inconvenience. In pharmaceutical and life sciences organizations, they manifest as regulatory sanctions, patient harm, operational inefficiencies, and failed AI initiatives. Each of these risks is interconnected, reinforcing the reality that data integrity is not optional, it is existential.

• Regulatory Compliance Data-integrity deficiencies can lead to FDA enforcement action and can affect product quality, inspections, and approvals. The controls and records needed depend on the applicable CGMP requirements, the system’s intended use, and the risk involved. FDA’s data-integrity guidance explains its expectations for complete, reliable CGMP records and risk-based controls.

• Patient Safety The most critical risk is patient harm. Inaccurate or incomplete data can lead to incorrect dosing, adverse events, or ineffective therapies. A single transcription error in a clinical trial record or a missing toxicology dataset in a regulatory submission can cascade into outcomes that directly affect patient lives. For AI systems, which often automate or accelerate decision‑making, the stakes are even higher: flawed data can amplify risks at scale.

• Operational Efficiency Poor data quality also undermines efficiency. Batch rejections, production delays, and costly rework are common outcomes when records are incomplete or inconsistent. These inefficiencies not only increase costs but also slow the delivery of therapies to patients. In competitive markets, operational drag caused by poor data quality can be the difference between leadership and obsolescence.

• AI Model Performance The adage “garbage in, garbage out” applies with particular force to AI. Models are only as good as the data they are trained on. If training datasets are biased, incomplete, or erroneous, the resulting models will produce unreliable predictions. In regulated industries, this is more than a technical failure, it is a compliance and ethical failure. AI that cannot be trusted undermines both innovation and patient safety.

Example in Practice

FDA issued a refuse-to-file letter for Zogenix’s original February 2019 Fintepla NDA. FDA’s later review records missing chronic nonclinical toxicity studies, incorrect SAS efficacy datasets, and the need for an extensive data-quality assessment before resubmission. The application was resubmitted in September 2019 and the later review recommended approval. FDA’s clinical review documents this history.

4.3 The Role of Data Culture

Data quality cannot thrive in isolation. Even the most advanced technologies and rigorous compliance frameworks will falter if the organizational culture does not support them. A strong data culture ensures that data quality is not seen as the responsibility of IT departments or compliance officers alone, but as a shared organizational value woven into the daily practices of scientists, engineers, managers, and executives.

When culture is strong, employees feel empowered to surface and address data issues without fear of reprisal. Instead of hiding anomalies or ignoring inconsistencies, they treat data integrity as a collective responsibility. This openness supports continuous improvement, as problems are corrected quickly and lessons are fed back into processes. Over time, this can create resilience: the organization learns from its mistakes and evolves toward higher standards of quality. PDA Quality Culture resources

Equally important, a healthy data culture fosters trust in AI‑driven decisions. AI models are only as reliable as the data they consume. If employees believe that data is consistently accurate, complete, and traceable, they are more likely to embrace AI insights in their work. Conversely, if data is perceived as unreliable, skepticism will undermine adoption, no matter how sophisticated the algorithms.

Consider a pharmaceutical company implementing AI for clinical trial analytics. In an organization with a weak data culture, staff may resist using AI outputs, doubting their validity because they know data entry is inconsistent or errors are often overlooked. In a strong data culture, however, employees trust the underlying data, collaborate across functions to validate results, and integrate AI insights into decision‑making. The difference is not just technical, it is cultural.

Ultimately, data culture is the bridge between compliance and innovation. It transforms data quality from a regulatory checkbox into a strategic enabler, ensuring that AI solutions are not only technically sound but also embraced by the people who use them.

5.1 Typical Data Quality Challenges

Even the most advanced pharmaceutical and life sciences organizations struggle with data quality. The challenges are rarely isolated; they often overlap, compounding risks across clinical, manufacturing, and regulatory domains. Understanding these common pitfalls is the first step toward remediation and building a foundation for trustworthy AI.

• Incomplete or Inaccurate Patient Records Patient records are the backbone of clinical research and pharmacovigilance. When records are incomplete or inaccurate, the consequences can be severe: misdiagnoses, inappropriate dosing, or overlooked adverse events. For AI systems, missing or erroneous data skews models, leading to unreliable predictions that can directly impact patient safety.

• Inconsistent Drug Formulation Data Manufacturing depends on precise formulation data. Inconsistencies, whether in ingredient measurements, batch documentation, or process parameters, introduce risks of dosage errors and compromised product quality. For AI models tasked with optimizing manufacturing, inconsistent data undermines their ability to detect patterns or predict failures.

• Delayed or Missing Pharmacovigilance Reports Pharmacovigilance relies on timely reporting of adverse drug reactions. Delays or omissions slow the detection of safety signals, leaving patients exposed to risks longer than necessary. In an AI‑enabled environment, missing reports reduce the dataset available for signal detection, weakening the system’s ability to protect patients.

• Fragmented Data Silos Data silos remain a persistent barrier in pharma. Clinical, manufacturing, and commercial teams often operate on separate systems, making collaboration and real‑time decision‑making difficult. Fragmentation prevents AI models from accessing the full spectrum of data, limiting their effectiveness and perpetuating inefficiencies.

• Poor Data Standardization Without standardized formats, units, and nomenclature, data integration becomes a compliance nightmare. Regulators expect harmonized datasets, and AI models require consistency to function properly. Poor standardization leads to duplicated effort, misinterpretation, and costly delays in submissions or analytics.

• Manual Data Entry Errors Manual transcription and review can introduce errors or omissions, particularly where data must be transferred between systems. Organizations should design controls appropriate to the process, including review, authorization, and validated electronic-record controls where applicable. FDA’s data-integrity guidance explains that electronic recordkeeping systems, including audit trails, can support CGMP recordkeeping requirements.

5.2 Remediation Strategies

Addressing data quality challenges requires more than quick fixes, it demands a systematic approach that blends technology, governance, and culture. Remediation strategies are most effective when they not only correct existing issues but also prevent them from recurring, creating a foundation of trust for both regulators and AI systems.

• Automated Data Validation Manual checks are no longer sufficient in complex, high‑volume environments. Machine learning‑powered tools, such as DataBuck, can recommend and enforce data quality rules at scale. These tools detect anomalies, flag inconsistencies, and even predict where errors are most likely to occur. Automation reduces human error and accelerates the validation process, ensuring that data entering AI pipelines is reliable from the start.

• Standardized Data Formats and Templates Consistency is critical for integration and compliance. By enforcing standardized formats and templates, organizations ensure that data collected in one department can be seamlessly understood and used in another. Standardization also simplifies regulatory submissions, reducing the risk of rejection due to formatting errors or inconsistent nomenclature.

• Regular Audits and Reviews Data quality is not static; it must be monitored continuously. Regular audits and reviews help organizations identify duplicates, incomplete records, and compliance gaps before they escalate. These reviews also provide evidence to regulators that data integrity is actively managed, reinforcing trust in the organization’s systems.

• Data Cleansing and Enrichment Even the best systems generate errors or gaps. Data cleansing involves identifying and correcting inaccuracies, while enrichment fills missing values and harmonizes datasets. For AI, enriched data provides more context and depth, improving model accuracy and reducing bias. Cleansing and enrichment transform raw data into a strategic asset.

• Data Lineage and Traceability Trust in data depends on knowing its origin and journey. Lineage tools track where data comes from, how it has been transformed, and how it is used. Traceability ensures accountability, enabling organizations to demonstrate compliance and quickly investigate anomalies. For AI, lineage provides transparency, helping explain how models reached their conclusions.

Example in Practice

An AWS post describing Bayer’s data science ecosystem says the platform uses data-mesh principles and supports multimodal data ingestion, storage, analytics, and machine-learning workflows across R&D domains. The post describes platform capabilities and intended benefits; it does not independently establish improvements in compliance, collaboration, or scientific outcomes. AWS’s Bayer case study

6.1 Data Governance and Stewardship

Strong data governance is the backbone of trustworthy AI in pharmaceutical and life sciences organizations. Governance ensures that data is not only well‑managed but also aligned with regulatory expectations, organizational goals, and ethical responsibilities. Stewardship, in turn, brings governance to life by assigning accountability and embedding data integrity into daily practice. Together, they create the guardrails that keep AI initiatives reliable, compliant, and sustainable.

• Establish Clear Data Ownership Data cannot be managed effectively if ownership is ambiguous. Assigning data stewards for each domain, clinical, manufacturing, pharmacovigilance, commercial, ensures that someone is accountable for data quality. Stewards act as custodians, bridging technical teams and business leaders, and making sure that data is accurate, complete, and fit for purpose.

• Implement Robust Data Governance Frameworks Governance frameworks define the policies, standards, and procedures that guide data management. These frameworks establish rules for how data is collected, stored, shared, and retired. In regulated environments, frameworks also ensure compliance with FDA, EMA, and ICH expectations. A well‑designed governance framework turns abstract principles into actionable practices.

• Continuous Monitoring and Feedback Loops Governance is not static; it requires ongoing vigilance. Dashboards and alerts provide real‑time visibility into data quality metrics, enabling organizations to detect issues before they escalate. Feedback loops ensure that lessons learned are incorporated into processes, creating a cycle of continuous improvement.

• Regular Training and Upskilling Governance succeeds only when people understand their role in maintaining data integrity. Regular training and upskilling ensure that staff at all levels, from lab technicians to executives, are fluent in data principles. Training reinforces that data quality is not just a compliance requirement but a shared organizational value.

• Change Management and Version Control In dynamic environments, changes to data, systems, and processes are inevitable. Documenting and controlling these changes is critical to maintaining integrity. Version control systems provide transparency, ensuring that every modification is traceable and auditable. This discipline prevents errors, reduces regulatory risk, and strengthens trust in AI outputs.

Example in Practice

The National Institutes of Health (NIH) Data Management and Sharing (DMS) Policy applies to research funded or conducted in whole or in part by NIH that generates scientific data, subject to the policy’s scope and exceptions. For research subject to the policy, investigators and institutions are expected to plan and budget for managing and sharing scientific data, submit a DMS Plan with the funding application or proposal, and comply with the approved plan. These requirements can support stewardship and data reuse, but they do not apply universally to all life-sciences organizations. NIH DMS Policy overview

6.2 Automation and Technology

Technology plays a pivotal role in transforming data quality from a manual, error‑prone process into a scalable, reliable system. By embedding validation, traceability, and quality checks directly into workflows, pharmaceutical and life sciences organizations can ensure that data is not only compliant but also ready to fuel advanced AI solutions.

• Automated Data Validation and Cleansing Manual reviews are slow and prone to oversight. Automated validation tools, often powered by machine learning, can enforce data quality rules at scale. These systems detect anomalies, correct errors, and even recommend improvements, reducing human error while improving scalability. Cleansing routines further harmonize datasets, filling gaps and standardizing values so that AI models receive consistent, trustworthy inputs.

• Data Lineage and Metadata Management Tools Traceability is essential in regulated environments. Lineage tools track the origin, transformations, and usage of every data point, while metadata management ensures that context, such as definitions, formats, and ownership, is preserved. Together, these technologies enhance audit readiness, making it easier to demonstrate compliance and explain AI outputs to regulators and stakeholders.

• Integration of Data Quality Checks into Workflows The most effective data quality practices are those embedded directly into daily operations. By integrating validation at the point of data entry and processing, organizations prevent errors before they propagate. This proactive approach ensures that data entering the system is already reliable, reducing the need for costly downstream corrections.

Example in Practice

Electronic batch records can embed completeness checks and support controlled review workflows. Organizations should measure any change in record accuracy or review time against a documented baseline and confirm that the system is validated for its intended use. For AI systems, these controls can help provide cleaner, more reliable datasets.

7.1 Overview of Data Governance Models

Data governance models define how data is managed, who is responsible, and how compliance is ensured. They provide the organizational scaffolding that determines whether data quality is treated as a strategic asset or left vulnerable to inconsistency and risk. While the specific design varies by company size, regulatory environment, and business priorities, three foundational models dominate the landscape: centralized, decentralized, and federated.

• Centralized Governance In a centralized model, a single core team, often led by the Chief Data Officer’s office, sets policies, monitors compliance, and manages data quality across the enterprise. This approach ensures uniform standards and strong oversight, which is particularly valuable in highly regulated industries. However, centralized governance can be slow to adapt and less flexible, as decisions must flow through a single authority. Smaller organizations or those operating under strict regulatory scrutiny often benefit most from this model, but beware of over‑centralization, which can slow responsiveness and risk creating a perception of bureaucracy.

• Decentralized Governance Decentralized governance places responsibility in the hands of individual business units or domains, with minimal central oversight. This model leverages domain expertise and allows for agility, as teams can tailor practices to their specific needs. The trade‑off is risk: without strong coordination, silos emerge, standards diverge, and compliance becomes harder to enforce. Large, diverse organizations in less regulated environments often adopt decentralized governance to maximize speed and autonomy.

• Federated Governance The federated model blends the strengths of centralized and decentralized approaches. Policies and standards are set centrally, but execution is distributed to domain experts who manage data within a common framework. This balance allows organizations to maintain enterprise‑wide consistency while leveraging specialized knowledge at the local level. Federated governance requires strong coordination and communication, but when implemented well, it creates a scalable system that aligns compliance with innovation.

Table 2: Comparison of Data Governance Models

In GxP environments, federated models are often preferred. They enable domain‑specific expertise, for example, clinical teams managing trial data or manufacturing teams overseeing batch records, while maintaining enterprise‑wide standards and compliance. This dual structure ensures that data governance is both practical and enforceable, supporting the rigorous demands of regulators while empowering innovation across the organization.

7.2 Data Governance Frameworks

While governance models define the structure of responsibility, frameworks provide the playbook for execution. They translate principles into detailed guidance on roles, policies, and lifecycle management, ensuring that data is not only well‑organized but also aligned with regulatory expectations and business goals. In pharmaceutical and life sciences organizations, where data integrity is inseparable from patient safety and compliance, frameworks serve as the scaffolding that keeps AI initiatives trustworthy and sustainable.

Several established frameworks are widely adopted across the industry:

• DAMA‑DMBOK (Data Management Body of Knowledge) DAMA-DMBOK is DAMA International’s body of knowledge for data management, covering disciplines that include data governance, data architecture, metadata, and data quality. It can help organizations define roles and responsibilities across functions. DAMA-DMBOK

• ISO/IEC 38505 ISO/IEC 38505-1:2026 provides principles for governing bodies on the effective, efficient, and acceptable use of data in organizations. It applies the ISO/IEC 38500 governance model to data and is relevant to boards, executives, and other governance participants. ISO/IEC 38505-1:2026

• ISPE GAMP (Good Automated Manufacturing Practice) GAMP guidance addresses computerized systems in regulated environments. ISPE published the GAMP Guide: Artificial Intelligence in July 2025; the publisher lists it as a 290-page guide on developing and using AI-enabled computerized systems in GxP areas. It is industry guidance, not a regulation. ISPE GAMP Guide: Artificial Intelligence

Example in Practice

Use organization-specific primary evidence before presenting a company’s platform architecture, governance model, or quantified outcomes as a case study. A centralized catalog and federated execution can illustrate a governance pattern, but they should not be attributed to Novartis here without support.

8.1 Key Principles and Standards

Pharmaceutical organizations operate in one of the most heavily regulated environments in the world, where data integrity is inseparable from patient safety and regulatory trust. To meet these expectations, and to enable AI solutions that are both reliable and explainable, companies must anchor their practices in globally recognized principles and standards. These frameworks provide the language, structure, and benchmarks that transform data quality from aspiration into enforceable reality.

• ALCOA+, ALCOA++ The ALCOA principles — Attributable, Legible, Contemporaneous, Original, Accurate — have long been considered the regulatory gold standard for data integrity. Expanded versions, ALCOA+ and ALCOA++, add further dimensions: Complete, Consistent, Enduring, Available, and Traceable. FDA’s CGMP data-integrity guidance describes ALCOA as attributable, legible, contemporaneously recorded, original or a true copy, and accurate. Organizations may use ALCOA+ or ALCOA++ terminology as internal frameworks, but the FDA guidance does not define either as a universal regulatory standard. Organizations should document their internal definitions and meet the requirements applicable to the records and systems at issue.

• FAIR Principles The FAIR principles — Findable, Accessible, Interoperable, and Reusable — are essential for collaborative research and AI adoption. FAIR ensures that data is not locked away in silos but can be discovered, shared, and integrated across systems and organizations. For example, interoperable datasets allow AI models to combine clinical, genomic, and manufacturing data to generate holistic insights. Reusability ensures that data collected today can support future studies, reducing duplication and accelerating discovery. FAIR transforms data into a living asset, ready to fuel innovation across the ecosystem²¹.

• ISO/IEC 5259 ISO/IEC 5259 provides comprehensive standards for data quality management in analytics and machine learning. It covers terminology, measures, management practices, process frameworks, and governance. Parts 1–4 were published in 2024, and Part 5 (Data quality governance framework) was published in 2025, completing the initial series. By adopting ISO/IEC 5259, pharma companies can align their AI initiatives with international best practices, ensuring that models are trained on data that meets rigorous quality thresholds. This standard bridges the gap between regulatory compliance and cutting‑edge analytics, making it particularly valuable in environments where AI must be both innovative and auditable²³.

8.2 Technologies and Tools

Technology is the engine that makes data governance and quality management scalable. While principles and frameworks provide the “why” and “what,” tools deliver the “how.” In pharmaceutical and life sciences organizations, where compliance, traceability, and AI readiness are non‑negotiable, the right technologies can transform fragmented data into a trusted, strategic asset.

• Data Lineage Tools Data-lineage platforms and metadata tools can capture data flows and support impact analysis, audit readiness, and provenance. The available granularity, including whether column-level lineage is captured, depends on the product, integrations, and implementation. OpenLineage is an open framework and specification for collecting and analyzing lineage metadata; it is not itself a universal column-level tracing product.

• Metadata Management Metadata management platforms catalog, track, and contextualize data assets. They ensure that datasets are not just stored but also described, searchable, and reusable. By embedding metadata, organizations make data more discoverable and interoperable, aligning with FAIR principles and enabling AI models to integrate diverse sources seamlessly.

• MLOps Platforms Platforms such as MLflow, AWS SageMaker, Kubeflow, DagsHub, and Iguazio support the full machine learning lifecycle: experiment tracking, model versioning, deployment, and monitoring. Integrated data quality checks ensure that models are trained and deployed on reliable datasets. MLOps bridges the gap between data science and operations, making AI reproducible, auditable, and scalable.

• Data Quality Tools Solutions like Talend, Ataccama, SAP Data Services, DataBuck, and Great Expectations automate validation, deduplication, and standardization. These tools reduce manual effort, enforce consistency, and provide continuous monitoring of data integrity. For pharma, they are essential in ensuring that clinical, manufacturing, and pharmacovigilance data meet regulatory thresholds.

• Feature Stores Tools such as Feast and Featureform manage and serve machine learning features with versioning and access controls. Feature stores ensure that AI models use consistent, validated inputs, reducing duplication and improving reproducibility. They also provide governance over how features are created, shared, and retired.

• Electronic Quality Management Systems (eQMS) eQMS platforms can automate document management, corrective and preventive action (CAPA) workflows, and training management. An eQMS does not itself establish compliance: the implemented system and associated procedures must be validated and controlled for their intended use and applicable requirements, including audit trails, authorized access, record retention, and change control. For closed systems subject to 21 CFR Part 11, the regulation requires controls including system validation, record protection and retrieval, authorized access, secure time-stamped audit trails, and documentation change control. 21 CFR Part 11

Table 3: Example Toolkits and Frameworks for Data Quality and Governance

Example in Practice

AWS describes Bayer’s Data Science Ecosystem as using Amazon SageMaker, a data-mesh architecture, and catalog capabilities to manage multimodal R&D data assets. AWS presents the platform as a foundation for standardized workflows and cross-domain data discovery; those statements should not be read as independently verified evidence of compliance, collaboration, or scientific outcomes. AWS’s Bayer case study

9.1 Regulatory Frameworks: FDA, EMA, ICH, WHO

Pharmaceutical data governance does not exist in a vacuum, it is shaped by a complex web of regulatory frameworks that define how data must be managed, validated, and preserved. These frameworks ensure that data integrity is not only a technical requirement but also a legal and ethical obligation. As AI becomes more deeply embedded in drug development and manufacturing, organizations should apply risk-based data-governance and documentation controls appropriate to each system’s intended use and applicable requirements.

• FDA (21 CFR Part 11, CGMP) The U.S. Food and Drug Administration requires that electronic records and signatures be trustworthy, attributable, and auditable. Under 21 CFR Part 11, organizations must demonstrate that digital systems meet the same standards of integrity as paper records. Data integrity breaches are treated as violations of Current Good Manufacturing Practice (CGMP), often resulting in warning letters, import alerts, and product recalls. For AI used to support regulated decisions, organizations should maintain documentation and controls proportionate to the model’s context of use and risk. FDA’s draft AI guidance

• European Commission EudraLex (Annex 11 and draft Annex 22) The European Commission’s EudraLex Volume 4 includes Annex 11 on computerized systems. The Commission held a public consultation from 7 July to 7 October 2025 on revisions to Chapter 4 and Annex 11 and on proposed new Annex 22 concerning AI. The Commission’s current EudraLex Volume 4 index lists Annex 11 but does not list a final Annex 22; Annex 22 should therefore be described as a draft until final publication is verified. The consultation material describes intended-use definition, performance metrics, training and test data, lifecycle oversight, change control, performance monitoring, and human review when necessary. European Commission consultation | EudraLex Volume 4 index

• EU AI Act The EU AI Act entered into force on 1 August 2024 and applies from 2 August 2026, subject to specified phased application dates. Prohibited-practice rules and AI-literacy obligations applied from 2 February 2025; specified governance, GPAI-model, and related provisions applied from 2 August 2025. Article 6(1)—covering AI systems that are safety components of, or are themselves, products covered by Annex I Union harmonisation legislation—applies from 2 August 2027. Organizations should assess each system’s intended purpose, product-regulatory status, and applicable AI Act category. Regulation (EU) 2024/1689, Article 113

• ICH Q9 (R1) The International Council for Harmonisation’s Q9 (R1) guideline on Quality Risk Management reached Step 4 on 18 January 2023 and is now in effect across ICH regions (FDA published 4 May 2023; EC implementation from 26 July 2023). It emphasizes risk‑based quality management that applies not only to physical processes but also to software and digital systems that impact product quality. By embedding risk management into governance, ICH Q9(R1) ensures that organizations proactively identify and mitigate data integrity risks before they affect patients or regulators. ICH Q9(R1) Quality Risk Management

• WHO / PIC/S The World Health Organization and the Pharmaceutical Inspection Co‑operation Scheme provide global guidance that aligns with ALCOA+ principles. Their frameworks reinforce the expectation that data must be attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, available, and traceable. This alignment ensures that multinational organizations can operate under a common set of expectations, reducing fragmentation across jurisdictions. WHO guideline on data integrity | PIC/S guidance on data integrity

Example in Practice

For AI that produces information or data intended to support regulatory decision-making, FDA’s January 2025 draft guidance presents a risk-based credibility-assessment framework. It states that model-development data should be fit for use—relevant and reliable, including accurate, complete, and traceable—and that credibility should be established for the model’s specific context of use and risk. The document is draft, nonbinding guidance; it is not a universal FDA or European requirement that all AI inputs, prompts, and outputs meet ALCOA+ standards. FDA draft guidance

9.2 Special Considerations

As pharmaceutical organizations integrate AI into drug development and manufacturing, regulators emphasize that data integrity principles must extend beyond traditional systems to cover the entire AI lifecycle. This requires not only technical safeguards but also governance practices that ensure transparency, accountability, and ethical use. Several special considerations stand out:

• Validation and Change Control For AI used to produce information or data that support FDA regulatory decision-making about a drug’s safety, effectiveness, or quality, FDA’s January 2025 draft guidance describes a risk-based credibility assessment tailored to the model’s specific context of use. The appropriate evidence, lifecycle maintenance, documentation, and controls depend on the use case, model risk, applicable requirements, and jurisdiction. The draft, nonbinding guidance does not create a universal validation or revalidation rule for every pharma AI system. FDA draft guidance

• Audit Trails Applicable GxP and electronic-record requirements may require audit trails and related controls for relevant records. Their design—including the events captured, user attribution, timestamps, review, and any documented justification—should be appropriate to the record, intended use, and risk. FDA’s data-integrity guidance describes audit trails that track data creation, modification, or deletion and recommends risk-based controls.

• Vendor Qualification Organizations should apply supplier and service-provider oversight appropriate to the outsourced activity, the system’s intended use, and applicable GxP requirements. Evidence may include quality agreements, assessments, and documentation of controls; the appropriate approach is risk-based rather than a universal audit requirement.

• Human Oversight Human review or oversight should be designed according to the use case, risk, and applicable legal or GxP requirements. The proposed European Commission Annex 22 consultation material calls for procedures for human review when necessary, while FDA and EMA’s good-AI-practice principles identify a human-centric, risk-based approach as a consideration rather than a standalone legal rule. European Commission consultation | FDA/EMA guiding principles

• Data Privacy and Security Applicable privacy and security obligations, including HIPAA and GDPR, must be addressed when protected or personal data are used. Under the EU AI Act, GPAI-model rules have applied since 2 August 2025; the Act generally applies from 2 August 2026, while Article 6(1) and its corresponding obligations apply from 2 August 2027. Privacy safeguards and security controls should protect sensitive data and support compliance with the requirements that apply to the particular use case. Regulation (EU) 2024/1689, Article 113

Example in Practice

FDA’s January 2025 draft guidance, "Considerations for the Use of AI to Support Regulatory Decision-Making for Drug and Biological Products," presents a risk-based credibility-assessment framework for a model’s specific context of use. It remains draft and nonbinding, and it does not address AI used for internal operational efficiencies, including drafting or writing, when that use does not affect patient safety, drug quality, or study-result reliability. In January 2026, FDA’s CDER and CBER collaborated with the European Medicines Agency (EMA) on Guiding Principles of Good AI Practice in Drug Development. The principles identify considerations for industry and product developers; they do not create a joint FDA/EMA/MHRA legal requirement. FDA/EMA Guiding Principles of Good AI Practice in Drug Development

10.1 Leadership Imperatives

Data quality and AI adoption are not simply technical challenges, they are leadership challenges. Executives set the tone for whether data is treated as a strategic asset or a compliance burden. Working with life sciences data transformation experts can help leaders navigate this critical shift. Their actions, priorities, and communication shape the culture that determines whether data initiatives succeed or stall. Several imperatives stand out for leaders seeking to embed data integrity and AI into the fabric of their organizations:

• Champion Data‑Driven Transformation Leaders must visibly support data and AI initiatives, not only by allocating resources but also by modeling desired behaviors. When executives reference data in decision‑making, highlight AI insights in strategy discussions, and personally sponsor data projects, they signal that transformation is not optional but central to the organization’s future.

• Set Clear Expectations and Accountability Data governance thrives when roles, responsibilities, and success metrics are unambiguous. Leaders must define who owns data quality, how performance will be measured, and what outcomes are expected. Clear accountability ensures that data culture is not diffuse but actionable, with every team understanding its role in maintaining integrity.

• Foster Psychological Safety Employees must feel safe to report data issues and experiment with new approaches without fear of reprisal. Psychological safety transforms data integrity from a compliance checkbox into a collaborative practice. When staff know they can surface anomalies or test innovative solutions without punishment, organizations become more resilient and adaptive.

• Invest in Data Literacy and Upskilling Data culture depends on competence. Leaders must provide training and development opportunities that build data and AI skills across all levels of the organization. From frontline staff learning to interpret dashboards to executives deepening their understanding of AI ethics, literacy ensures that data is not intimidating but empowering.

• Celebrate Successes and Learn from Failures Recognition reinforces the value of data‑driven work. Leaders should celebrate achievements in data projects, highlighting how they improved compliance, efficiency, or innovation. Equally important, failures should be treated as learning opportunities rather than setbacks. This mindset encourages experimentation and signals that progress is measured not only by outcomes but also by growth.

Example in Practice

DBS Bank has publicly described fostering experimentation and learning as part of its transformation. Such practices can support innovation when paired with appropriate accountability, risk management, and controls. DBS CEO reflections

While leadership sets the vision, it is organizational behaviors that determine whether data culture truly takes root. These behaviors translate principles into daily practices, shaping how employees interact with data, collaborate across functions, and embrace continuous improvement. When embedded consistently, they create an environment where data is not only trusted but actively leveraged to drive innovation and compliance.

• Empowerment Empowerment means giving employees access to data and the tools to use it effectively. When staff can explore dashboards, run analyses, or query datasets without barriers, they begin to see data as a resource rather than a constraint. Empowerment democratizes data, ensuring that insights are not confined to specialists but available to everyone who needs them.

• Collaboration Breaking down silos is essential for data culture. Cross‑functional teamwork allows clinical, manufacturing, regulatory, and commercial teams to share insights and solve problems together. Collaboration ensures that data is not fragmented but integrated, enabling AI models to draw from a complete and diverse set of inputs.

• Transparency Transparency builds trust. Sharing data, insights, and lessons learned openly across the organization prevents duplication of effort and fosters accountability. Transparency also strengthens compliance, as audit trails and open reporting demonstrate that data integrity is actively managed. For AI adoption, transparency ensures that outputs are explainable and credible.

• Continuous Improvement Data practices must evolve alongside technology and regulatory expectations. Regular reviews, feedback loops, and the adoption of new tools ensure that data quality is not static but continuously refined. Continuous improvement signals that the organization is committed to resilience, learning, and innovation.

Example in Practice

Gulf Bank announced a Data Ambassadors program intended to build data awareness and capabilities among employees. Organization-specific outcomes should be measured against a documented baseline. Gulf Bank announcement

Building AI readiness is not a single initiative but a structured journey. It requires organizations to align vision, engage stakeholders, strengthen governance, deploy enabling technologies, and embed cultural practices that sustain long‑term value. The roadmap below outlines the critical stages of this journey, showing how each step builds upon the last to create a resilient foundation for trustworthy AI.

1. Define Vision and Objectives The journey begins with clarity. Executives must articulate a data and AI vision aligned with business and regulatory goals, identifying key drivers such as patient safety, operational efficiency, and innovation. A clear vision provides direction and ensures that every initiative ties back to strategic priorities.

2. Engage Stakeholders Transformation cannot succeed in silos. Mapping and involving decision‑makers across R&D, manufacturing, quality, IT, and compliance ensures cross‑functional alignment. Communicating the business value and expected outcomes of data initiatives builds buy‑in and momentum.

3. Assess Current State Organizations must understand where they stand before charting a path forward. Data quality and culture assessments reveal strengths, gaps, and risks across data, technology, processes, and people. This diagnostic step provides the evidence base for prioritizing actions.

4. Develop Governance and Quality Frameworks Governance provides the guardrails for sustainable change. Selecting the right model, centralized, federated, or hybrid, and establishing policies, standards, and procedures ensures accountability, compliance, and consistency. Frameworks turn principles into enforceable practices.

5. Implement Enabling Technologies Technology makes governance scalable. Deploying data lineage, metadata management, MLOps, and eQMS tools embeds quality into workflows. Automated validation and monitoring reduce human error and accelerate compliance, ensuring that AI systems are trained on reliable datasets.

6. Upskill and Empower Teams Culture depends on competence. Training staff on data integrity principles (ALCOA+), AI, and regulatory requirements fosters literacy and confidence. Empowering teams to collaborate across functions ensures that data stewardship is shared, not siloed.

7. Monitor, Audit, and Improve Readiness is not static. Continuous monitoring, feedback loops, and regular audits ensure that data practices evolve alongside regulatory expectations and technological advances. Dashboards and KPIs provide visibility, driving accountability and improvement.

8. Sustain and Scale Finally, successful practices must be embedded into the organizational DNA. Scaling technologies and cultural behaviors across the enterprise ensures resilience, long‑term value, and readiness for future innovation. Sustaining momentum transforms data quality from a project into a way of life.

Table 4: Roadmap for Data Quality and Culture Readiness

Common Pitfalls to Avoid

• Treating data quality as a one‑time project Many organizations launch short‑term clean‑up efforts but fail to embed ongoing governance and monitoring. Without continuous improvement, data quality quickly erodes and undermines AI reliability.

• Overlooking cultural adoption Investing in tools and frameworks without fostering a shared data culture leads to resistance, siloed practices, and inconsistent stewardship. Technology alone cannot sustain readiness if people aren’t empowered and aligned.

• Neglecting Regulatory Foresight Focusing only on current compliance requirements can leave organizations unprepared for evolving standards. Building flexible governance and proactive monitoring ensures resilience as regulations adapt to AI maturity.

These pitfalls reinforce the importance of treating readiness as a living system, one that balances governance, technology, and culture for long‑term success.

12.1 Economic and Public Health Returns

Investing in mature data quality and governance practices delivers measurable returns that extend beyond compliance. The benefits ripple across cost structures, productivity, regulatory standing, and ultimately patient safety, making data integrity a driver of both economic performance and public health outcomes.

• Cost Savings Robust quality management reduces product defects, waste, rework, and recalls. By preventing errors at the source, organizations lower total costs and protect margins. These savings are not only financial but reputational, as fewer recalls strengthen trust among regulators, patients, and investors.

• Productivity Gains Automation and digital workflows can reduce manual handling and support more timely review. Organizations should quantify any productivity or cycle-time improvement against a documented baseline and account for implementation, validation, and change-management costs.

• Regulatory Compliance Strong data practices reduce the likelihood of warning letters, import alerts, and product holds. Compliance becomes proactive rather than reactive, with organizations demonstrating to regulators that data integrity is embedded into daily operations. This reduces risk and accelerates approvals.

• Patient Safety and Public Health Reliable data ensures that therapies are safe, effective, and consistently available. By strengthening supply chains and reducing variability, organizations protect patients from adverse events and ensure timely access to critical treatments. Public health benefits when trust in therapies is reinforced by transparent, high‑quality data.

Example in Practice

FDA’s economic-perspective report describes a biopharmaceutical manufacturing-site example with intermediate quality-management practices. The example reports product defects reduced by more than 50%, waste reduced by 75%, and 25% of staff redirected to other activities. These are case-study results, not generalizable benchmarks for all sites. FDA report

The return on investment (ROI) from AI in pharmaceutical and life sciences organizations is directly tied to the quality of the data that fuels it. When data governance and integrity are strong, AI becomes a catalyst for accelerated innovation, operational efficiency, and risk mitigation. Conversely, poor data quality undermines trust, slows adoption, and increases regulatory exposure.

• Accelerated Innovation High‑quality data enables faster, more accurate AI‑driven drug discovery and development. Clean, standardized datasets allow algorithms to identify promising compounds, optimize trial designs, and predict patient outcomes with greater precision. This accelerates the pipeline from research to market, reducing time‑to‑therapy and expanding opportunities for breakthrough innovation.

• Operational Efficiency AI‑powered automation reduces manual effort, shortens cycle times, and improves decision‑making. From automating regulatory submissions to streamlining manufacturing batch reviews, AI eliminates repetitive tasks and frees staff to focus on higher‑value activities. Efficiency gains translate into lower costs, faster delivery, and improved agility in responding to market and regulatory demands.

• Risk Mitigation Robust data governance and quality reduce the risk of AI model failures, bias, and regulatory penalties. By embedding traceability, audit trails, and validation into AI workflows, organizations ensure that models are not only effective but also compliant. Risk mitigation strengthens trust among regulators, patients, and investors, making AI adoption sustainable.

Example in Practice

For generative AI used in regulatory-document workflows, organizations should establish a defined context of use, measure quality and review outcomes against a baseline, and maintain controls proportionate to whether the output supports a regulated decision. FDA’s draft framework focuses on AI used to produce information or data intended to support regulatory decision-making regarding drug safety, effectiveness, or quality. FDA draft guidance

13.1 Bayer: Cloud-Based Data Science Ecosystem

An AWS post, co-authored by a Bayer engineering lead, describes Bayer’s R&D Data Science Ecosystem as using next-generation Amazon SageMaker, data-mesh principles, and a hybrid mesh lakehouse architecture. AWS says the platform is intended to unify data ingestion, storage, analytics, and AI/ML workflows and to support cataloging of multimodal assets across R&D domains.

AWS reports that Bayer was positioned to onboard more than 300 TB of biomarker data and that the platform was laying the groundwork to operationalize more than 25 high-value ML use cases and support more than 100 data scientists. These are AWS/Bayer platform descriptions and forward-looking capacity figures, not independently verified measures of compliance, scientific breakthroughs, or regulatory confidence.

Reported Platform Capabilities

• Data architecture: A data-mesh approach and hybrid mesh lakehouse architecture for multimodal R&D data.

• Workflow tooling: Integrated tooling for data, analytics, and machine-learning work.

• Planned scale: Capacity plans for biomarker-data onboarding, ML use cases, and data-scientist support.

Read AWS’s Bayer case study.

Novartis has publicly described enterprise-wide data and analytics platforms and initiatives to make data available across its business. Those disclosures do not substantiate the article’s specific claims about a multi-cloud architecture, a centralized catalog with federated governance, or ingestion of 9 TB from more than 80 sources. Use company and independent primary evidence before presenting platform design or quantified outcomes as a case study.

Pharmaceutical manufacturers may use electronic batch records, deviation-management tools, and predictive-maintenance analytics to reduce manual handling and identify process issues earlier. Any claimed performance improvement should be measured against a documented baseline and assessed within the validated system's intended use. For AI that supports regulatory decision-making on drug safety, effectiveness, or quality, FDA's draft guidance describes a risk-based credibility assessment tailored to the model's context of use; it is draft and nonbinding. FDA draft guidance

AI and structured-content tools may assist with drafting, retrieval, and consistency checks in regulatory-document workflows, but they do not eliminate the need for accountable human review and controls appropriate to the output's role. For AI that produces information or data to support regulatory decision-making about drug safety, effectiveness, or quality, FDA's draft guidance recommends defining the context of use and establishing credibility evidence commensurate with model risk. The guidance is draft and nonbinding. FDA draft guidance

• FDA Guidance for Industry: Data Integrity and Compliance With Drug CGMP

• ISPE GAMP Guide: Artificial Intelligence

• WHO Technical Report Series No. 1033, Annex 4: WHO Guideline on Data Integrity

• Pistoia Alliance FAIR Toolkit

• ISO/IEC 5259 Series: Data Quality for Analytics and Machine Learning

• DAMA-DMBOK: Data Management Body of Knowledge

• Gartner AI Maturity Model and Roadmap Toolkit

• PDA Quality Culture Assessment Tool

• Front Line Genomics: Guide to the FAIR Principles in Biopharma

• FDA Economic Perspective on Quality Management Initiatives

• Data quality and culture are foundational, not optional, for AI success in pharma and life sciences.

• Trustworthy data fuels reliable AI insights, ensuring models deliver actionable outcomes that regulators, clinicians, and patients can depend on.

• Robust data culture embeds accountability and continuous improvement, making data integrity part of everyday decision‑making.

• Governance frameworks and advanced toolkits (lineage, metadata, MLOps, eQMS) provide the structure and scalability needed for compliance and innovation.

• Leadership and organizational behaviors, from championing transformation to fostering psychological safety, are critical to sustaining data integrity.

• Regulatory alignment is essential: risk-based data-integrity practices and applicable legal requirements, supplemented where appropriate by voluntary frameworks such as ALCOA+, FAIR, and ISO/IEC 5259 and by FDA/EMA guidance, can support patient safety and audit readiness. FDA data-integrity guidance | ISO/IEC 5259-5

• The ROI is clear: stronger compliance, reduced costs, improved productivity, accelerated innovation, and enhanced public health outcomes.

• Pharma and life sciences leaders who invest in data quality and culture readiness unlock AI’s full potential, driving competitive advantage and building lasting trust with regulators, patients, and society.

Data quality and data culture are not optional add-ons but foundational enablers of successful, compliant, and impactful AI solutions in pharmaceutical and life sciences organizations. High-quality, trustworthy data ensures that AI models deliver reliable, actionable insights, while a robust data culture embeds data-driven decision-making and continuous improvement throughout the enterprise. In regulated environments, these pillars are essential for patient safety, regulatory compliance, operational efficiency, and competitive advantage. By adopting best-in-class governance models, leveraging advanced toolkits and frameworks, and fostering leadership and organizational behaviors that prioritize data integrity, pharma and life sciences leaders can unlock the full potential of AI, driving innovation, improving outcomes, and building lasting trust with regulators, patients, and the public. As AI matures and regulation advances, organizations that unite data integrity with ethical innovation will set the future standard for trust and excellence in life sciences.

For further guidance, consult the referenced frameworks, standards, and case studies, and engage with data strategy consultants to tailor these principles to your organization's unique context and goals.

1. ALCOA+ Principles & Data Integrity In Pharma - Apotech
2. ALCOA, ALCOA+ and ALCOA++ Principles - Pharma Guideline
3. ALCOA+ Principles: A Guide to GxP Data Integrity - IntuitionLabs
4. How to Measure Data Quality: Essential Metrics for Pharmaceutical - GMP Pros
5. 5 Worse Incidents Caused by Data Quality Issues in the Pharmaceutical Industry - Digna
6. Quality Culture - PDA
7. Mastering Quality Culture Assessment: A Pathway to Transforming - Compliance Architects
8. Quality Management Initiatives in the Pharmaceutical Industry - FDA
9. Building AI-Ready Data: Why Quality Matters More Than Quantity - Elucidata
10. Artificial Intelligence in Pharmaceutical Analysis: A Paradigm Shift - IJPS Journal
11. Bioinformatics and artificial intelligence in genomic data analysis - Springer
12. Guidance for Industry: Data Integrity and Compliance With Drug CGMP - FDA
13. Best AI Use-Cases for Quality teams in Life Science and Pharma - Acodis
14. How Bayer transforms Pharma R&D with a cloud-based data science ecosystem - AWS
15. Practicing Data Stewardship During Research - NIH
16. Data Governance Models: Choose Centralized, Federated, or Hybrid - Atlan
17. Data Governance Best Practices in 2025 - Appsilon
18. GAMP Guide: Artificial Intelligence - ISPE
19. ISPE releases new GAMP guide for artificial intelligence - BioProcess International
20. Life Sciences Digital Transformation: Novartis Case Study - Accenture
21. FAIR for Pharma - Pistoia Alliance
22. A Guide to the FAIR Principles in Biopharma - Front Line Genomics
23. ISO/IEC 5259-1:2024 - Artificial intelligence: Data quality for analytics and ML
24. Top 25 Data Lineage Tools for Reliable Analytics Governance - OvalEdge
25. 25 Top MLOps Tools You Need to Know in 2025 - DataCamp
26. Quality 4.0 in Pharma: A 2026 ROI & Economic Analysis - IntuitionLabs
27. FDA Data Integrity Guidance: ALCOA+ and CGMP Compliance - Legal Clarity
28. Validating Generative AI in GxP: A 21 CFR Part 11 Framework - IntuitionLabs
29. Data Protection and Privacy in AI-Based Learning Systems - L-TEN
30. HIPAA Compliance for AI in Digital Health - Foley & Lardner
31. FDA Proposes Framework to Advance Credibility of AI Models - FDA
32. Catalysts Of Change: Leadership's Role In Pharma Data Science - Forbes
33. Gartner AI Maturity Model & Roadmap Toolkit
34. Zogenix, Inc. - Glancy Prongay & Murray LLP
35. Solving Good Documentation Practice Errors - BioBridge Global
36. Life Sciences Digital Transformation: Novartis Case Study - Accenture
37. Quality Risk Management Q9(R1) Step 4 (Adopted January 2023) - ICH
38. ICH Q9 Quality risk management - Scientific guideline - EMA
39. ICH Q9 (R1) – What is new and how to navigate it - GxP-CC
40. TRS 1033 - Annex 4: WHO Guideline on data integrity
41. Guidance on Data Integrity - PIC/S
42. An inside look at how McKinsey helped DBS become an AI-powered bank
43. CEO reflections - DBS Bank
44. Embracing Failure Culture at DBS Bank - ASEF
45. Gulf Bank Launches Second Edition of "Data Ambassadors" Program
46. Data Champions: The Secret Ingredient to Upskilling - DataCamp
47. Gulf Bank CDO Drives Digital Transformation - Rackspace Technology
48. Guiding Principles of Good AI Practice in Drug Development (FDA and EMA)
49. EU AI Act — Implementation Timeline
50. ISO/IEC 5259-5:2025 — Data quality governance framework
51. EMA Draft Annex 22: Artificial Intelligence (public consultation, July–October 2025)
52. 2025 FDA Warning Letter Trends in Pharma — Leucine